ASCO 2026: Highlights and analysis

Apalutamide plus ADT improves surgical outcomes in high-risk prostate cancer

Darolutamide shows less cognitive decline than enzalutamide in advanced prostate cancer

mCRPC treatment sequencing: Need for optimal therapy at the earliest opportunity

Enzalutamide plus radium-223 extends survival in bone metastatic prostate cancer

ASCO GU 2026: Updates in metastatic prostate cancer

ASCO GU 2026: Updates in localised prostate cancer

Oncofertility counseling and fertility preservation in premenopausal women with early breast cancer

Aromatase inhibitors improve disease-free survival in HR+/HER2+ early breast cancer: ALTTO 10-year follow-up

ESMO 2025: Latest developments in endometrial cancer

ESMO 2025: Highlights and analysis

Best practice in precision medicine for prostate cancer